FDA proposes restrictions on bulk compounding of weight-loss drugs
The proposal targets pharmacy compounding from bulk substances, the route many sellers used during the GLP-1 shortage period.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 17 02:45 ETSource: Meteo.gr
The wire
- 01FDA has proposed restrictions on compounding popular weight-loss drugs from bulk drug substances, according to the report.
- 02Compounders and telehealth operators still supplying GLP-1 copies would face narrower legal ground if the proposal is finalized.
- 03The report is brief and does not specify which substances, effective dates or comment deadlines are involved.
From the source
Read at meteo.grfda proposes restrictions on compounding bulk popular weight loss drugs
